{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.tibsovo:1 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.tibsovo%3A1",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00389,
    "timestamp_received": "2026-04-24T03:24:07.241054+00:00Z",
    "timestamp_returned": "2026-04-24T03:24:07.244944+00:00Z",
    "trace_id": "02c1ba71-2979-4fea-b44c-d49dc7a5cc4b"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.tibsovo:1",
      "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.",
      "initial_approval_date": "2023-05-12",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tibsovo-epar-public-assessment-report_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Cholangiocarcinoma",
      "raw_therapeutics": "Tibsovo (ivosidenib)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.tibsovo",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Tibsovo (ivosidenib) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo",
          "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Les Laboratoires Servier.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Tibsovo",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "ivosidenib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2023-05-12",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-01-15",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}